Availability of New Tests, Completed Acquisitions, Public Offering Plans, and Prestigious Awards - Research Report on LabCorp, Teleflex, Orexigen, HeartWare and Quintiles

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Laboratory Corp. of America Holdings (NYSE: LH), Teleflex Incorporated (NYSE: TFX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), HeartWare International Inc. (NASDAQ: HTWR), and Quintiles Transnational Holdings Inc. (NYSE: Q). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Laboratory Corp. of America Holdings Research Report

On December 2, 2013, Laboratory Corp. of America Holdings (LabCorp) announced the nationwide availability of a suite of tests to identify patients with BRCA mutations who are at an increased risk for breast, ovarian and other cancers, called the BRCAssure tests. "The National Comprehensive Cancer Network and the American College of Obstetricians and Gynecologists recognize the importance of screening for BRCA 1 and BRCA2 mutations, and LabCorp's BRCAssure panels will make this testing more available," stated Dr. Mark Brecher, LabCorp's Chief Medical Officer. "LabCorp's comprehensive, full gene sequencing BRCAssure tests will give healthcare providers the mutation information necessary to assist in patient counseling." The Company informed that the BRCAssure tests will be available through LabCorp as well as Integrated Genetics and Integrated Oncology, members of LabCorp's Specialty Testing Group. The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c267_LH

Teleflex Incorporated Research Report

On December 2, 2013, Teleflex Inc. (Teleflex) announced the completion of its acquisition of Vidacare Corp., the leading provider of intraosseous, or inside the bone, access devices. The Company does not expect the acquisition to significantly impact Teleflex's 2013 revenue or adjusted earnings per share expectations. The transaction is expected to contribute approximately $68 million to $72 million of revenue and approximately $0.10 to $0.15 in adjusted earnings per share in FY 2014 (excluding non-recurring purchase accounting items and other acquisition and integration related costs). The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9c7d_TFX

Orexigen Therapeutics, Inc. Research Report

On December 2, 2013, Orexigen Therapeutics, Inc. (Orexigen) announced its intention to offer $100 million aggregate principal amount of convertible senior notes due 2020 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offer, the Company expects to grant the initial purchasers a 13-day option to purchase up to an additional $15 million aggregate principal amount of such Notes. Further, the Company stated that it intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds to in-license or acquire new businesses or products. The Full Research Report on Orexigen Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1b1a_OREX

HeartWare International Inc. Research Report

On December 1, 2013, HeartWare International Inc. (HeartWare) announced its acquisition of CircuLite Inc., a developer of SYNERGY® Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent. Under the terms of the merger agreement, HeartWare has acquired all of the issued and outstanding equity interests of CircuLite for a consideration of $30 million, plus certain contingent success payments due upon satisfaction of regulatory and commercial milestones not to exceed $320 million in the aggregate over a ten-year period. "The partial-support system developed by CircuLite represents the industry's most intriguing platform for the treatment of patients with earlier stage heart failure," said Doug Godshall, President and CEO at HeartWare. "CircuLite has pioneered the partial-assist approach and demonstrated that this technique can significantly enhance the quality of life for this group of patients, which is believed to be a substantially larger population than the end-stage heart failure patients that HeartWare currently treats with our full-support Ventricular Assist Devices (VADs)." The Full Research Report on HeartWare International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0461_HTWR

Quintiles Transnational Holdings Inc. Research Report

On November 22, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that it has been the recipient of the Scrip Awards' Best Contract Research Organization honors for the second year running, as well as the Best Technological Development in Clinical Trials for Quintiles Infosario Safety System for the first time. Commenting on this honor, Paula Brown Stafford, President, Clinical Development at Quintiles said, "It is an honor to be recognized once again for our sustained leadership in the sector. I'd like to dedicate this prestigious award to Quintiles' employees worldwide - the true foundation of our business." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9f5c_Q

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner